Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Psychopharmacology May 16, 2008 Karsten Heekeren, Jörg Daumann, Anna Neukirch et al. 158 citations
Both S-ketamine (an NMDA antagonist) and DMT (a 5HT2A agonist) reduced mismatch negativity (MMN) and impaired performance on a continuous performance test in healthy volunteers, but the effects differed. S-ketamine produced a more pronounced overall reduction in MMN and specifically affected the frontal source of MMN, while DMT did not. These distinct neurocognitive profiles suggest that the two classes of hallucinogens model different aspects of psychosis.